Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CGTX
Strong SellSinkerCognition Therapeutics, Inc. · Healthcare · United States · $97M · Avg Vol: $479K/d
COMPANY DESCRIPTION
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. Its proprietary discovery platform has identified candidates like elayta (CT1812), which targets the sigma-2 receptor complex to protect synapses from toxic oligomers. The company occupies a specialized niche in neurodegenerative research, focusing on disease-modifying mechanisms for Alzheimer's and dry AMD.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.29 | -0.31 | -0.86 | -0.32 | — | -0.17 | -0.30 | -0.22 | — |
| Shares | 89.5M | 89.5M | 59.9M | 88.9M | -0.7% | 95.1M | — | — | — |
| Debt | 1.5M | 1.2M | 0.8M | 0.6M | -24.4% | 0.6M | — | — | — |
| Equity | 40.2M | 24.5M | 18.8M | 34.3M | -5.2% | — | — | — | — |
| Op CF | -18.5M | -16.0M | -28.5M | -24.6M | — | -17.7M | — | — | — |
| Inv CF | -0.2M | -0.1M | -4.0K | 9.0K | — | — | — | — | — |
| Fin CF | 5.5M | 4.5M | 23.6M | 36.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CGTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CGTX | Cognition Therapeutics, Inc.(you) | $97M | 13 | Strong Sell |
| GUTS | Fractyl Health, Inc. | $105M | 14 | Strong Sell |
| MAIA | MAIA Biotechnology, Inc. | $81M | 12 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| TENX | Tenax Therapeutics, Inc. | $80M | 12 | Strong Sell |
| VRCA | Verrica Pharmaceuticals Inc. | $98M | 8 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 12 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%